What is Enanta Pharmaceuticals Inc (ENTA) stock price today?

Enanta Pharmaceuticals Inc (ENTA) currently trades at $13.87 per share. The stock has a market capitalization of $386.25M and a P/E ratio of —x.

Is ENTA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Enanta Pharmaceuticals Inc has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Enanta Pharmaceuticals Inc's revenue and earnings?

Enanta Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $66.98M with profit margins of -106.80%. Earnings per share (EPS) is $-3.21.

Is ENTA stock overvalued or undervalued?

Based on our DCF model, Enanta Pharmaceuticals Inc's intrinsic value is $25.41, representing a margin of safety of 43.92%. The stock currently trades at a P/E of —x.

ENTA

Enanta Pharmaceuticals Inc

NASDAQ: ENTA · HEALTHCARE · BIOTECHNOLOGY

$13.87

+1.17% today

Updated 2026-04-29

Market cap

$386.25M

P/E ratio

—

P/S ratio

5.77x

EPS (TTM)

$-3.21

Dividend yield

—

52W range

$5 – $17

Volume

0.2M

Market cap

$386.25M

P/E ratio

—

P/S ratio

5.77x

EPS (TTM)

$-3.21

Dividend yield

—

52W range

$5 – $17

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.3

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$19.86

+43.19%

12-Month target

—

Intrinsic (DCF)

$25.41

Margin of safety

+43.92%

1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 43.92% below intrinsic value

Risks

- Thin margins at -106.80%

- Negative free cash flow $-11.84M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$86.16M	$79.20M	$67.64M	$65.32M	$66.98M
Net income	$-121.75M	$-133.82M	$-116.05M	$-81.89M	$-11.94M
EPS	—	—	—	—	$-3.21
Free cash flow	$-86.91M	$-112.21M	$-96.71M	$-32.17M	$-11.84M
Profit margin	-141.31%	-168.95%	-171.58%	-125.36%	-106.80%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-11	VANCE, TERRY	Buy	20,000	—
2026-03-11	RUSSELL, LESLEY	Buy	20,000	—
2026-03-11	PETERSON, KRISTINE	Buy	20,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ENTA	$386.25M	25	3.3	2.0	6.7	5.0	+43.92%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Enanta Pharmaceuticals Inc trades at $13.87. Our Smart Value Score of 25/100 indicates the stock is weak. TTM revenue stands at $66.98M. with profit margins at -106.80%. Our DCF model estimates intrinsic value at $25.41.

Frequently asked questions

What is Enanta Pharmaceuticals Inc's stock price?

Enanta Pharmaceuticals Inc (ENTA) trades at $13.87.

Is Enanta Pharmaceuticals Inc overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell). DCF value $25.41.

What is the price target of Enanta Pharmaceuticals Inc (ENTA)?

The analyst target price is $19.86, representing +43.2% upside from the current price of $13.87.

What is the intrinsic value of Enanta Pharmaceuticals Inc (ENTA)?

Based on our DCF model, intrinsic value is $25.41, a +43.9% margin of safety versus $13.87.

What is Enanta Pharmaceuticals Inc's revenue?

TTM revenue is $66.98M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio5.77x

ROE-60.00%

Beta1.00

50D MA$13.58

200D MA$11.65

Shares out0.03B

Float0.02B

Short ratio—

Avg volume0.2M

Performance

1 week-5.00%

1 month+9.28%

3 months+2.23%

YTD-15.60%

1 year—

3 years—

5 years—

Compare

ENTA vs LLY →ENTA vs JNJ →ENTA vs ABBV →Stock screener →